WEST PHARMACEUTICAL SERVICES INC
Congressional Trades
Whale Activity
- Increased306
- New123
- Held128
- Decreased290
- Closed62
- No prior filing35
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 6.7M | $2.49B | increased |
| FMR LLC | 6.0M | $2.22B | increased |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.6M | $1.71B | decreased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 4.1M | $1.53B | increased |
| STATE STREET CORP | 3.3M | $1.23B | decreased |
| Artisan Partners Limited Partnership | 2.0M | $744.4M | decreased |
| GEODE CAPITAL MANAGEMENT, LLC | 1.9M | $715.2M | increased |
| Bank of New York Mellon Corp | 1.7M | $644.7M | decreased |
| MORGAN STANLEY | 1.6M | $583.7M | decreased |
| T. Rowe Price Investment Management, Inc. | 1.6M | $577.3M | decreased |
| Invesco Ltd. | 1.2M | $440.5M | increased |
| JPMORGAN CHASE & CO | 1.1M | $414.8M | decreased |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
Recent Insider Transactions
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Favorite Annette FSr. VP & Chief HR Officer | Sale | −2,524 | $365.00 | $921K | Sep 15, 2026 | Form 4 ↗ |
| Favorite Annette FSr. VP & Chief HR Officer | Option exercise | +2,524 | $89.64 | $226K | Sep 15, 2026 | Form 4 ↗ |
| Favorite Annette FSr. VP & Chief HR Officer | Sale | −2,500 | $355.00 | $888K | Sep 14, 2026 | Form 4 ↗ |
| Favorite Annette FSr. VP & Chief HR Officer | Option exercise | +2,500 | $89.64 | $224K | Sep 14, 2026 | Form 4 ↗ |
| Favorite Annette FSr. VP & Chief HR Officer | Sale | −2,500 | $345.00 | $863K | Sep 11, 2026 | Form 4 ↗ |
| Favorite Annette FSr. VP & Chief HR Officer | Option exercise | +2,500 | $89.64 | $224K | Sep 11, 2026 | Form 4 ↗ |
| Favorite Annette FSr. VP & Chief HR Officer | Sale | −2,500 | $340.81 | $852K | Sep 8, 2026 | Form 4 ↗ |
| Favorite Annette FSr. VP & Chief HR Officer | Option exercise | +2,500 | $89.64 | $224K | Sep 8, 2026 | Form 4 ↗ |
| Favorite Annette FSr. VP & Chief HR Officer | Sale | −2,818 | $340.81 | $960K | Sep 8, 2026 | Form 4 ↗ |
| Favorite Annette FSr. VP & Chief HR Officer | Option exercise | +2,818 | $83.47 | $235K | Sep 8, 2026 | Form 4 ↗ |
| Favorite Annette FSr. VP & Chief HR Officer | Sale | −2,817 | $340.81 | $960K | Sep 8, 2026 | Form 4 ↗ |
| Favorite Annette FSr. VP & Chief HR Officer | Option exercise | +2,817 | $83.47 | $235K | Sep 8, 2026 | Form 4 ↗ |
| McMahon Robert W.SVP & Chief Financial Officer | Tax withholding | −2,764 | $351.37 | $971K | Aug 11, 2026 | Form 4 ↗ |
| McMahon Robert W.SVP & Chief Financial Officer | Option exercise | +6,355 | — | — | Aug 11, 2026 | Form 4 ↗ |
| McMahon Robert W.SVP & Chief Financial Officer | Tax withholding | −346 | $351.37 | $121K | Aug 11, 2026 | Form 4 ↗ |
| McMahon Robert W.SVP & Chief Financial Officer | Option exercise | +794 | — | — | Aug 11, 2026 | Form 4 ↗ |
| Campbell Shane AldenSVP, Proprietary Segment | Tax withholding | −135 | $312.07 | $42K | May 12, 2026 | Form 4 ↗ |
| Campbell Shane AldenSVP, Proprietary Segment | Option exercise | +474 | — | — | May 12, 2026 | Form 4 ↗ |
| Campbell Shane AldenSVP, Proprietary Segment | Tax withholding | −84 | $312.07 | $26K | May 12, 2026 | Form 4 ↗ |
| Campbell Shane AldenSVP, Proprietary Segment | Option exercise | +296 | — | — | May 12, 2026 | Form 4 ↗ |
Fund Holders
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 2.2M | $805.2M | 0.04% | Jun 30, 2026 |
| VANGUARD 500 INDEX FUND VANGUARD INDEX FUNDS | 1.8M | $657.1M | 0.04% | Jun 30, 2026 |
| VANGUARD MID-CAP INDEX FUND VANGUARD INDEX FUNDS | 1.5M | $549.5M | 0.25% | Jun 30, 2026 |
| iShares Core S&P 500 ETF iShares Trust | 971.7K | $348.8M | 0.04% | Jun 30, 2026 |
| Fidelity Contrafund | 941.6K | $338.0M | 0.19% | Jun 30, 2026 |
| VANGUARD GROWTH INDEX FUND VANGUARD INDEX FUNDS | 940.5K | $337.6M | 0.09% | Jun 30, 2026 |
| T. Rowe Price Mid-Cap Growth Fund, Inc. | 894.8K | $321.2M | 1.39% | Jun 30, 2026 |
| Fidelity 500 Index Fund Fidelity Concord Street Trust | 917.1K | $312.8M | 0.04% | Aug 31, 2026 |
| State Street(R) SPDR(R) S&P 500(R) ETF Trust | 856.2K | $307.4M | 0.04% | Jun 30, 2026 |
| Strategic Advisers Fidelity U.S. Total Stock Fund Fidelity Rutland Square Trust II | 875.0K | $298.5M | 0.11% | Aug 31, 2026 |
Mutual funds and ETFs whose N-PORT filings list WST's shares (CUSIP 955306105), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Corporate Lobbying
No lobbying filings found naming WEST PHARMACEUTICAL SERVICES INC as the client.
Government Contracts
No federal contract awards found for WEST PHARMACEUTICAL SERVICES INC.
U.S. Patents
No USPTO patent applications found for WEST PHARMACEUTICAL SERVICES INC.
Annual Financials
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $3.07B | $2.89B | $2.95B | $2.89B | $2.83B |
| Operating income | $584.9M | $569.9M | $676.0M | $734.0M | $752.3M |
| Net income | $493.7M | $492.7M | $593.4M | $585.9M | $661.8M |
| Diluted EPS | $6.79 | $6.69 | $7.88 | $7.73 | $8.67 |
| Operating cash flow | $754.8M | $653.4M | $776.5M | $724.0M | $584.0M |
| Cash and equivalents | $791.3M | $484.6M | $853.9M | $894.3M | $762.6M |
| Total assets | $4.27B | $3.64B | $3.83B | $3.62B | $3.31B |
| Total liabilities | $1.09B | $961.1M | $948.5M | $931.9M | $978.4M |
| Shareholders' equity | $3.18B | $2.68B | $2.88B | $2.68B | $2.34B |
As WEST PHARMACEUTICAL SERVICES INC tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 17, 2026 ↗
Stock Splits
- 2-for-1Stock splitSep 27, 2013
Split dates and ratios from the price history · Close Prices from Tiingo.com
Material Events (8-K)
- 8-K · Items 2.02, 7.01, 9.01Results of operations · Reg FD disclosureOct 29, 2026
EDGAR ↗ - 8-K · Items 1.01, 1.02, 2.03, 9.01Material agreement · Termination of agreement · Direct financial obligationOct 26, 2026
EDGAR ↗ - 8-K · Items 2.02, 7.01, 9.01Results of operations · Reg FD disclosureJul 23, 2026
EDGAR ↗ - 8-K · Items 1.01, 9.01Material agreementJul 14, 2026
EDGAR ↗ - 8-K · Items 5.02, 7.01, 9.01Officer / director change · Reg FD disclosureJun 1, 2026
EDGAR ↗ - 8-K/A · Items 1.05, 9.01May 20, 2026
EDGAR ↗ - 8-K · Items 1.05, 7.01, 9.01Reg FD disclosureMay 11, 2026
EDGAR ↗ - 8-K · Items 5.07, 9.01Shareholder voteMay 5, 2026
EDGAR ↗




